📊 BYAH Key Takeaways
Is Park Ha Biological Technology Co., Ltd. (BYAH) a Good Investment?
Park Ha Biological Technology lacks sufficient financial data disclosure on SEC EDGAR, with only 1 metric available and no income statement, balance sheet, or cash flow information. The absence of fundamental financial data prevents meaningful analysis of profitability, financial health, or operational performance, indicating either a recently listed shell company or serious reporting deficiencies.
Park Ha Biological Technology shows very high gross margins and a debt-light balance sheet, but the core business remains extremely small at roughly $2.5 million of annual revenue with limited growth over the last three years. Fiscal 2025 swung to a very large net loss driven mainly by share-based compensation, which makes reported profitability weak and earnings quality questionable even though operating cash flow stayed positive. Fundamentals point to a company with adequate liquidity but fragile growth quality and insufficient operating scale.
Why Buy Park Ha Biological Technology Co., Ltd. Stock? BYAH Key Strengths
- Listed on Nasdaq exchange suggesting regulatory compliance baseline
- Operations in cosmetics/personal care sector with established market demand
- Potential for future data disclosure as company matures
- High gross margin profile, with gross profit exceeding 90% of revenue in fiscal 2025
- Improved liquidity after year-end 2025 cash rose to about $3.8 million and current assets materially exceeded current liabilities
- No meaningful interest-bearing debt burden, which limits balance-sheet leverage risk
BYAH Stock Risks: Park Ha Biological Technology Co., Ltd. Investment Risks
- Virtually no financial data available for fundamental analysis - major red flag
- No revenue, earnings, or profitability metrics disclosed
- Zero insider trading activity in past 90 days suggests minimal institutional engagement
- Possible shell company status or foreign company with limited US reporting
- Cannot assess solvency, liquidity, or operational viability
- High risk of total capital loss due to unknown financial condition
- Revenue growth has been weak and inconsistent, with annual sales roughly flat over the 2023-2025 period
- Fiscal 2025 reported a very large net loss because operating expenses, especially share-based compensation, surged far above revenue
- Operating cash flow fell sharply in fiscal 2025, and loans receivable from franchisees are large relative to the company’s revenue base
Key Metrics to Watch
- Revenue and revenue growth rates once disclosed
- Operating margins and net profitability
- Balance sheet strength - cash position and leverage ratios
- Quarterly SEC filings completeness and consistency
- Revenue mix and growth in franchise fees versus product sales
- Operating cash flow and normalization of general and administrative expense after the 2025 share-based compensation spike
Park Ha Biological Technology Co., Ltd. (BYAH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BYAH Profit Margin, ROE & Profitability Analysis
BYAH vs Consumer Sector: How Park Ha Biological Technology Co., Ltd. Compares
How Park Ha Biological Technology Co., Ltd. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Park Ha Biological Technology Co., Ltd. Stock Overvalued? BYAH Valuation Analysis 2026
Based on fundamental analysis, Park Ha Biological Technology Co., Ltd. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Park Ha Biological Technology Co., Ltd. Balance Sheet: BYAH Debt, Cash & Liquidity
BYAH Revenue Growth, EPS Growth & YoY Performance
BYAH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Park Ha Biological Technology Co., Ltd. (CIK: 0001986247)
❓ Frequently Asked Questions about BYAH
What is the AI rating for BYAH?
Park Ha Biological Technology Co., Ltd. (BYAH) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BYAH's key strengths?
Claude: Listed on Nasdaq exchange suggesting regulatory compliance baseline. Operations in cosmetics/personal care sector with established market demand. ChatGPT: High gross margin profile, with gross profit exceeding 90% of revenue in fiscal 2025. Improved liquidity after year-end 2025 cash rose to about $3.8 million and current assets materially exceeded current liabilities.
What are the risks of investing in BYAH?
Claude: Virtually no financial data available for fundamental analysis - major red flag. No revenue, earnings, or profitability metrics disclosed. ChatGPT: Revenue growth has been weak and inconsistent, with annual sales roughly flat over the 2023-2025 period. Fiscal 2025 reported a very large net loss because operating expenses, especially share-based compensation, surged far above revenue.
What is BYAH's revenue and growth?
Park Ha Biological Technology Co., Ltd. reported revenue of N/A.
Does BYAH pay dividends?
Park Ha Biological Technology Co., Ltd. does not currently pay dividends.
Where can I find BYAH SEC filings?
Official SEC filings for Park Ha Biological Technology Co., Ltd. (CIK: 0001986247) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BYAH's EPS?
Park Ha Biological Technology Co., Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BYAH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Park Ha Biological Technology Co., Ltd. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BYAH stock overvalued or undervalued?
Valuation metrics for BYAH: ROE of N/A (sector avg: 18%), net margin of N/A (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy BYAH stock in 2026?
Our dual AI analysis gives Park Ha Biological Technology Co., Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BYAH's free cash flow?
Park Ha Biological Technology Co., Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does BYAH compare to other Consumer stocks?
Vs Consumer sector averages: Net margin N/A (avg: 8%), ROE N/A (avg: 18%), current ratio N/A (avg: 1.5).